SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
SpaceX Stock Plunges 16% as KeyBanc Warns Valuation May Be Overstretched 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
NHTSA Investigates Fatal Tesla Model 3 Crash in Texas Amid Ongoing Autopilot and FSD Safety Scrutiny 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
AMSTERDAM, the Netherlands, Feb. 15, 2016 -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, announced today that Dan Soland, Chief Executive Officer, will present at the RBC Capital Markets 2016 Global Healthcare Conference on February 24, 2016 at 2:05 p.m. EST / 20:05 pm CET. The conference is being held February 23 - 24, 2016 at The Palace Hotel in New York City.
The webcast, including a slide presentation, can be accessed through the following link: http://www.veracast.com/webcasts/rbc/healthcare2016/26211430508.cfm or by accessing the link displayed in the "Events" section on the "Media" page of the uniQure website at: http://www.uniqure.com/news/calendar-of-events/. The replay of the webcast will be available one hour after the conclusion of the live event and archived on the uniQure website for at least 30 days following the webcast.
About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with CNS, liver/metabolic and cardiovascular diseases. www.uniQure.com
CONTACT: uniQure:
Eva Mulder
Direct : +31 20 240 6103
Main: +31 20 240 6000
[email protected]
Media inquiries:
Gretchen Schweitzer
MacDougall Biomedical Communications
Direct: +49 172 861 8540
Main: +49 89 2424 3494 or +1 781 235 3060
[email protected]
